Replies to post #195643 on Biotech Values

[DewDiligence]

PLX monetizes Gaucher drug, Elelyso, by selling worldwide rights—except Brazil—to PFE; PFE also buys 6% equity stake in PLX:

http://finance.yahoo.com/news/protalix-biotherapeutics-sells-share-collaboration-113000945.html

All told, PLX will receive $46M of cash from this transaction ($36M from the divestiture and $10 from the sales of equity), yielding a pro forma 9/30/15 cash balance of about $80M.